GSK hands over work on potential Ebola vaccine to US’s Sabin institute
Enabling Sabin to build on the scientific progress GSK has delivered up to phase II lifts the likelihood the candidate vaccines may help prevent potential future outbreaks, GSK Vaccines says
06 August 2019 - 14:01
London — British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses, as an Ebola outbreak in Democratic Republic of Congo (DRC) continues.
The vaccine candidates — two designed to protect against Ebola and one against the Marburg virus — will be transferred to the Sabin Vaccine Institute in Washington, DC, GSK said in a statement...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.